Fosun Pharma (02196): Empagliflozin Metformin Extended-Release Tablets (III) Approved for Registration

Zhitong Finance APP News, Fosun Pharmaceutical (02196) announced that recently, its holding subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for the drug registration application of Empagliflozin Metformin Hydrochloride Extended-Release Tablets (III) (hereinafter referred to as "the drug"). The approved indication is for use in conjunction with dietary control and exercise, applicable to adult patients with type 2 diabetes who are currently receiving treatment with Empagliflozin and Metformin Hydrochloride, aimed at improving blood glucose control in these patients.